425
Views
21
CrossRef citations to date
0
Altmetric
Original Articles

Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer

&
Pages 521-530 | Received 25 Mar 2015, Accepted 24 Sep 2016, Published online: 28 Oct 2016
 

ABSTRACT

The risk of infection attributable to mTOR inhibitors has not been determined. Databases from PubMed and abstracts presented at the American Society of Clinical Oncology meetings were searched. Eligible studies included randomized controlled trials, in which everolimus or temsirolimus was compared with placebo. A total of 12 trials were included. The attributable incidences of all-grade and high-grade infections to mTOR inhibitors were 9.3% (95% confidence interval (CI): 5.8–14.6%) and 2.3% (95% CI: 1.2–4.4%) respectively. The risk varied widely with tumor types (p <.001). There was substantial risk of infection attributable to mTOR inhibitors everolimus and temsirolimus.

Declaration of interest

Shenhong Wu is a speaker for Novartis and Pfizer. Christine A. Garcia has no conflicts of interest. The authors alone are responsible for the content and writing of the article.

ORCID

Christine A. Garcia http://orcid.org/0000-0002-0367-7813

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.